Korro Bio, Inc. (KRRO)
NASDAQ: KRRO · Real-Time Price · USD
11.18
-0.02 (-0.18%)
May 14, 2026, 11:39 AM EDT - Market open
Korro Bio Revenue
Korro Bio had revenue of $3.84M in the twelve months ending March 31, 2026, down -20.31% year-over-year. In the year 2025, Korro Bio had annual revenue of $6.39M with 181.46% growth.
Revenue (ttm)
$3.84M
Revenue Growth
-20.31%
P/S Ratio
42.04
Revenue / Employee
$78,408
Employees
49
Market Cap
161.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.39M | 4.12M | 181.46% |
| Dec 31, 2024 | 2.27M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Black Diamond Therapeutics | 70.00M |
| Protalix BioTherapeutics | 52.74M |
| ProQR Therapeutics | 19.19M |
| Pyxis Oncology | 13.86M |
| Kazia Therapeutics | 1.27M |
| Molecular Partners AG | 856.30K |
KRRO News
- 5 days ago - Korro Bio upgraded to Buy from Hold at JonesResearch - TheFly
- 5 days ago - JonesResearch upgrades ‘fast-follower’ Korro Bio to Buy - TheFly
- 7 days ago - Korro Bio reports Q1 EPS ($1.69), consensus ($1.98) - TheFly
- 7 days ago - Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 8 days ago - Korro to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences - GlobeNewsWire
- 4 weeks ago - Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Korro Bio files to sell 7.65M shares of common stock for holders - TheFly